Clinical Trial TitleA Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL)
National Clinical Trial Number:NCT03809000
Clinical Trial Protocol Description:
The purpose of this study is to compare the usual treatment of radiation and hormone therapy with the usual treatment plus the study drug, enzalutamide. The addition of the study drug to the usual treatment could increase the time without disease progression.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have pathologically proven adenocarcinoma confirmed by prostatectomy performed within 10 years.
- Have a PSA level (≥0.2 ng/mL) within 90 days prior to registration.
- Have hemoglobin ≥9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to registration.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.